Develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies designed to treat cancer and immune disorders. The company focuses on off-the-shelf natural killer (NK) cell and T‑cell therapies, with value tied largely to clinical trial outcomes, regulatory milestones, and partnership...
This page tracks all publicly disclosed congressional trades in Fate Therapeutics, Inc. (FATE), a company in the Healthcare sector. 1 member of Congress has disclosed trades in this stock, including 0 purchases and 1 sale. All data is sourced from STOCK Act Periodic Transaction Reports filed with the House and Senate disclosure offices.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-01-31 | Daniel Goldman | sell | $1K – $15K |